NasdaqGS - Delayed Quote • USD
Vir Biotechnology, Inc. (VIR)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:34 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 9 |
| Avg. Estimate | -1.05 | -1.04 | -4.1 | -3.98 |
| Low Estimate | -1.32 | -1.23 | -4.94 | -5.66 |
| High Estimate | -0.79 | -0.91 | -3.43 | -2.84 |
| Year Ago EPS | -1.06 | -1.45 | -4.59 | -4.1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 8 | 8 |
| Avg. Estimate | 11.71M | 9.06M | 40.52M | 41.61M |
| Low Estimate | 2.57M | 4.79M | 19.71M | 17.69M |
| High Estimate | 39.4M | 21.3M | 121.8M | 106.2M |
| Year Ago Sales | 50.1M | 3.8M | 86.18M | 40.52M |
| Sales Growth (year/est) | -76.60% | 138.60% | -53.00% | 2.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.87 | -1.2 | -1.21 | -1.01 |
| EPS Actual | -1.06 | -1.45 | -1.22 | -0.86 |
| Difference | -0.19 | -0.25 | -0.01 | 0.15 |
| Surprise % | -21.80% | -20.80% | -0.80% | 14.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.05 | -1.04 | -4.1 | -3.98 |
| 7 Days Ago | -1.05 | -1.04 | -4.1 | -3.98 |
| 30 Days Ago | -1.05 | -1.03 | -4.09 | -3.98 |
| 60 Days Ago | -1.05 | -1.03 | -4.1 | -4.01 |
| 90 Days Ago | -1.1 | -1.13 | -4.29 | -3.76 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VIR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.90% | -- | -- | 6.50% |
| Next Qtr. | 28.30% | -- | -- | 12.00% |
| Current Year | 10.70% | -- | -- | 5.30% |
| Next Year | 2.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 7.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/15/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 2/23/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/14/2024 |
| Downgrade | JP Morgan: Overweight to Neutral | 1/29/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/23/2024 |
| Maintains | Needham: Buy to Buy | 11/3/2023 |
Related Tickers
SAGE Sage Therapeutics, Inc.
13.69
+0.81%
ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%
RLAY Relay Therapeutics, Inc.
6.37
+3.49%
CVAC CureVac N.V.
2.3300
+0.87%
BLUE bluebird bio, Inc.
0.9228
+1.13%
CYTK Cytokinetics, Incorporated
65.34
+0.83%
VERV Verve Therapeutics, Inc.
6.16
-0.96%
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
ALEC Alector, Inc.
5.25
+9.15%
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%